한국형 우울장애 약물치료 알고리듬 2021 (VI): 비약물학적 생물치료
Korean Medication Algorithm Project for Depressive Disorder 2021 (VI): Non-Pharmacological Biological Treatments
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives The Korean Medication Algorithm Project for Depressive Disorder 2021 (KMAP-DD 2021) was made to update new researches and data. This study focused on non-pharmacological biological treatments. Methods Ninety-seven psychiatrists with extensive clinical experience in the non-pharmacological biological treatment of depressive disorder were primary selected and a questionnaire was sent to each of them by mail, 65 of the 97 replied. Results Electroconvulsive therapy (ECT) was recommended as an initial strategy for major depressive disorder, severe depressive disorder with/without psychotic features with urgent suicidal risk, or a severe depressive episode with psychotic features in pregnant patients, for non-responders on pharmacotherapy for a moderate depressive episode, and as a second strategy for non-responders on antidepressant monotherapy or combination therapy combined with physical illness. For pregnant women with a severe episode of major depressive disorder, repetitive transcranial magnetic stimulation (rTMS) was preferred as a first-line strategy, and as a second strategy for non-responders on combined antipsychotic and antidepressant therapy and non-responders with comorbidity and physical illness. Complementary or novel treatment was not recommended as the first-line treatment strategy for depressive disorder, but transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), light therapy, and omega-3 fatty acid nutritional therapy were second-line treatment strategies. Conclusion ECT and rTMS are initial strategies in specific clinical situations. Preferences for complementary or novel treatments such as tDCS, light therapy, and omega-3 fatty acid nutritional therapy have increased gradually, but in practice, their usages are still limited.
Abstract
Objectives The Korean Medication Algorithm Project for Depressive Disorder 2021 (KMAP-DD 2021) was made to update new researches and data. This study focused on non-pharmacological biological treatments. Methods Ninety-seven psychiatrists with extensive clinical experience in the non-pharmacological biological treatment of depressive disorder were primary selected and a questionnaire was sent to each of them by mail, 65 of the 97 replied. Results Electroconvulsive therapy (ECT) was recommended as an initial strategy for major depressive disorder, severe depressive disorder with/without psychotic features with urgent suicidal risk, or a severe depressive episode with psychotic features in pregnant patients, for non-responders on pharmacotherapy for a moderate depressive episode, and as a second strategy for non-responders on antidepressant monotherapy or combination therapy combined with physical illness. For pregnant women with a severe episode of major depressive disorder, repetitive transcranial magnetic stimulation (rTMS) was preferred as a first-line strategy, and as a second strategy for non-responders on combined antipsychotic and antidepressant therapy and non-responders with comorbidity and physical illness. Complementary or novel treatment was not recommended as the first-line treatment strategy for depressive disorder, but transcranial direct current stimulation (tDCS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), light therapy, and omega-3 fatty acid nutritional therapy were second-line treatment strategies. Conclusion ECT and rTMS are initial strategies in specific clinical situations. Preferences for complementary or novel treatments such as tDCS, light therapy, and omega-3 fatty acid nutritional therapy have increased gradually, but in practice, their usages are still limited.
참고문헌 (23)
- Waraich P, "Prevalence and incidence studies of mood disorders : a systematic review of the literature", Can J Psychiatry, 49, pp.124~138 (2004)
- The epidemiological survey of mental disorders in Korea 2011, "Seoul National University College of Medicine", Ministry of Health and Welfare, ~ (2012)
- Alexopoulos GS, "Pharmacotherapy of depression in older patients : a summary of the expert consensus guidelines", J Psychiatr Pract, 7, pp.361~376 (2001)
- Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders : major depression summary", Bipolar Disord, 22, pp.788~804 (2020)
- Fochtmann LJ, "Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition", FOCUS, 3, pp.34~42 (2005)
- Suehs B, "Major depressive disorder algorithms" (2008), Texas Department of State Health Service
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
- Depression:treatment and management of depression in adults, including adults with a chronic physical health problem, "National Institute for Health and Clinical Excellence", National Institute for Health and Clinical Excellence, ~ (2009)
- Lee MS, "The Korean Medication Algorithm for Major Depressive Disorder(KMAMDD) : report of the Korean Society of Depressive and Bipolar Disorders", Int J Psychiatry Clin Prac, 10, pp.186~194 (2006)
- 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
- Seo JS, "The Korean Medication Algorithm for Depressive Disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- Alexopoulos GS, "The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients", Postgrad Med, pp.1~86 (2001)
- Altshuler LL, "The expert consensus guideline series. Treatment of depression in women", Postgrad Med, pp.1~107 (2001)
- Milev RV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments", Can J Psychiatry, 61, pp.561~575 (2016)
- Bauer M, "Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines", Int J Psychiatry Clin Pract, 21, pp.166~176 (2017)
- Herrmann LL, "Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression : a review", J Clin Psychiatry, 67, pp.1870~1876 (2006)
- Lam RW, "Repetitive transcranial magnetic stimulation for treatment-resistant depression : a systematic review and metaanalysis", Can J Psychiatry, 53, pp.621~631 (2008)
- Palm U, "tDCS for the treatment of depression : a comprehensive review", Eur Arch Psychiatry Clin Neurosci, 266, pp.681~694 (2016)
- Rigonatti SP, "Transcranial direct stimulation and fluoxetine for the treatment of depression", Eur Psychiatry, 23, pp.74~76 (2008)
- Brunoni AR, "The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial", JAMA Psychiatry, 70, pp.383~391 (2013)
- Oliveira JF, "Acute working memory improvement after tDCS in antidepressant-free patients with major depressive disorder", Neurosci Lett, 537, pp.60~64 (2013)
- Brunoni AR, "Enhancement of affective processing induced by bifrontal transcranial direct current stimulation in patients with major depression", Neuromodulation, 17, pp.138~142 (2014)